Overview

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the ability of 3 commercially available phosphorus binders (calcium acetate, sevelamer carbonate, and lanthanum carbonate) to achieve and maintain a phosphorus level in the normal range in patients with chronic kidney disease.
Phase:
N/A
Details
Lead Sponsor:
Denver Nephrologists, P.C.
Collaborators:
DaVita Dialysis
Fresenius Medical Care North America
Genzyme, a Sanofi Company
Novartis Pharmaceuticals
Shire
Treatments:
Calcium
Calcium acetate
Sevelamer